Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.
R. Caleb Kovell, MDFour-year data on the prostatic urethral lift and data on an investigational water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting. The BPH/LUTS take-home messages were presented by R. Caleb Kovell, MD, of the University of Pennsylvania, Philadelphia.
Experience with holmium laser enucleation of the prostate (HoLEP) showed linear improvement in enucleation, AUA Symptom Score (AUA-SS) improvement of at least 50% across range of prostate volume, and greater improvement with larger glands.
Four-year follow-up of a trial of the prostatic urethral lift (UroLift, Neotract) in 206 men showed sustained improvement from baseline, including a 46% decrease in International Prostate Symptom Score (IPSS), no sustained erectile or ejaculatory dysfunction, and 19 repeat procedures.
Robot-assisted water-jet ablation (AquaBeam System, PROCEPT BioRobotics) required an average of 38 minutes in the operating room and decreased IPSS from 22.9 to 6.8 at 6 months and increased Qmax from 7.8 to 16.7 cc/sec at 1 year, with no retrograde ejaculation, urinary incontinence, or erectile dysfunction seen.
Ejaculation-sparing thulium laser ablation allowed 165 of 167 patients to leave the hospital without a catheter, led to sustained increase in Qmax, maintenance of ejaculatory function in 56%, and significant decreases in IPSS at 1 and 6 months.
A 10-year follow-up survey of 100 treated with HoLEP showed durable decline in AUA-SS from 21.9 to 5.1, 95% patient satisfaction, 3.5% need for ancillary surgical procedures, and mean PSA value of 1.57 ng/mL.
Subscribe to Urology Times to get monthly news from the leading news source for urologists.